HCA Healthcare, US40412C1018

HCA Healthcare stock: Mizuho raised target to USD 570

Published on 11/16/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
HCA Healthcare stock reflects Mizuho's updated view with an Outperform rating. The note cites a better legislative outlook for acute-care providers.

Mizuho shifts its HCA view

  • Mizuho retained an Outperform rating for HCA Healthcare.
  • The analyst cited a more favorable legislative outlook for acute-care providers.
HCA Healthcare, US40412C1018, Illustration mit AI erstellt.

HCA Healthcare stock: Mizuho analyst Ann Hynes raised the price target to USD 570 from USD 495 on Wednesday, November 11, while keeping an Outperform rating, according to Markets Insider.

What Mizuho cited

The analyst said the acute-care group was benefiting from an improved legislative outlook. The note also pointed to investor optimism that political developments could support bipartisan compromise on legislative and regulatory pressures affecting access to health insurance.

Investor context

Mizuho said the recent momentum could prove sustainable. For investors, the revised view places the focus on reimbursement policy, insurance coverage and the regulatory environment alongside HCA Healthcare's operating performance.

HCA Healthcare stock traded at EUR 465.45 on Lang & Schwarz at 16:01 CET on Monday, November 16, 2026.

HCA Healthcare at a glance

  • Company: HCA Healthcare
  • ISIN: US40412C1018
  • Ticker: HCA
  • Trading venue: Lang & Schwarz
  • Price: EUR 465.45 at 16:01 CET on November 16, 2026
  • Analyst action: Mizuho raised its target and retained Outperform on November 11, 2026

Broader U.S. market conditions remain relevant for healthcare shares; investors can follow Current market reports.

More news and analyses on HCA Healthcare stock.

Disclaimer...
en | US40412C1018 | HCA HEALTHCARE | boerse | 70521425 | bgmi